Retinalamin — Khavinson bioregulator — retina / ophthalmology
Retinalamin is a polypeptide complex derived from bovine retina. Targets retinal tissue specifically. Restores retinal cell gene expression, promotes photoreceptor survival, reduces oxidative damage to RPE cells, and improves electroretinogram (ERG) function. Used clinically in Russia for glaucoma, age-related macular degeneration, and diabetic retinopathy. Administered as parabulbar (periocular) injection in ophthalmic settings.
Overview
This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.
Compound Class
Khavinson bioregulator — retina / ophthalmology
Mechanism of Action
Retinalamin is a polypeptide complex derived from bovine retina. Targets retinal tissue specifically. Restores retinal cell gene expression, promotes photoreceptor survival, reduces oxidative damage to RPE cells, and improves electroretinogram (ERG) function. Used clinically in Russia for glaucoma, age-related macular degeneration, and diabetic retinopathy. Administered as parabulbar (periocular) injection in ophthalmic settings.
Regulatory Status
Not FDA approved. Russian pharmaceutical drug (Retinalamin for injection). Approved in Russia for retinal diseases.
Evidence Level
Moderate — Approved pharmaceutical drug in Russia with clinical data for multiple retinal diseases. Epitalon's n=162 RCT was for retinitis pigmentosa (different compound but related).